Author

Zhe Wang

Cincinnati Children's Hospital Medical CenterORCID 0000-0002-9129-4125Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Zhe Wang8 papers · City Of Hope National Medical Center

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cell type annotation· 1 Assay:CITE-seq· 1 Research Focus:clustering· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Andrew J. CarrolliD· 1 shared Ann‐Kathrin EisfeldiD· 1 shared Bailee Nicole KainiD· 1 shared Caner SayginiD· 1 shared Chang LiuiD· 1 shared Daniel T. StarczynowskiiD· 1 shared Darren LeeiD· 1 shared Deedra NicoletiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andrew J. CarrollORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genotype-immunophenotype relationships in NPM1-mutant AML clonal evolution uncovered by single cell multiomic analysis

Morgan Drucker, Darren Lee, M. B. Bowman, Xuan Zhang, Bailee Nicole Kain, Deedra Nicolet, Roopsha Bandopadhyay, Varsha Singh, Zhe Wang, Richard Maury Stone, Caner Saygin, Krzysztof Mrózek, Andrew J. Carroll, Daniel T. Starczynowski, Ross L. Levine, , Linde A. Miles

This study uses single-cell multiomic analysis to reveal genotype-immunophenotype relationships and clonal evolution in NPM1-mutant AML across disease stages.

Blood · Apr 8, 2026Peer-reviewedCancer Biology

Contrastive Learning-Enhanced Drug Metabolite Prediction Drives the Discovery of an Orally Bioavailable RSK4 Inhibitor for Esophageal Cancer

Huan He, Manzhan Zhang, Xiaoxiao Yang, Shuai He, Xiayu Shi, Feng Hu, Chang Liu, Xingsen Zhang, Na Chen, Xiaoqian Zhu, Leihao Zhang, Tianyu Ye, Rong Zhang, Yanru Yang, Rui Wang, , Shiliang Li

The paper develops ConMeter, a metabolite prediction model, and uses it to design an orally bioavailable RSK4 inhibitor with improved bioavailability and anti-tumor efficacy against esophageal cancer.

bioRxiv · Jun 2, 2025 · PreprintCancer Biology